FDA Announces PCSK9 Advisory Panels, Clarifies Potential Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
Indications to be weighed over two days in June for Amgen’s Repatha and Sanofi/Regeneron’s Praluent include use for LDL-lowering in patients who can’t take statins, and for increasing HDL and Apo A-1.